Dr. Reddy's Laboratories Limited logo
Dr. Reddy's Laboratories Limited RDY
$ 11.88 0.13%
report update icon

Quarterly report 2025-Q4
added 09-10-2026

Dr. Reddy's Laboratories Limited Financial Ratios 2025-2011 | RDY

Brief overview of Dr. Reddy's Laboratories Limited's multiples and efficiency

This overview follows the five latest available observations from 2021 through 2025.

The current valuation set is P/E 0.21x (median 0.21x), EV/EBITDA 2.14x (median 2.14x), P/S 0.04x (median 0.04x). The multiple basket looks neutral against its history, differing from median levels by roughly 0%.

Current measures of operating quality are ROE 17%, ROA 11.6%, ROCE 19.8%. Overall capital returns are high. The business uses resources efficiently and provides strong fundamental support for its valuation.

The cash conversion cycle lengthened from 155.5 days to 230 days, or 74.5 days. More cash is tied up in operations.

Overall assessment

Dr. Reddy's Laboratories Limited's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.

Annual Financial Ratios Dr. Reddy's Laboratories Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

0.2 0.2 0.2 0.1 0.6 31.6 - - - - - - - - 1939.0

P/S

0.0 0.0 0.0 0.0 0.1 3.5 -71.1 -56.0 -71.1 -124.8 -139.7 292.8 - - 358.4

EPS

67.9 66.9 54.3 142.1 103.9 117.6 113.3 59.1 72.2 117.3 - - - - -

EV (Enterprise Value)

153 B 111 B 94.4 B 89.3 B 88.4 B 83.7 B -4.41 B -4.32 B -647 M -2.82 B -3.24 B 10.2 B 12.7 B 11.4 B 9.38 B

EBITDA per Share

86.2 81.4 68.8 178 146 273 -3.38 -3.46 -3.35 -1.76 -1.48 0.599 0.338 0.338 1.76

EV/EBITDA

2.1 1.6 1.7 3.0 3.6 0.6 80.4 133.0 238.8 120.2 186.0 277.1 348.0 254.4 71.4

PEG

-0.02 -0.0 -0.0 -0.0 -0.0 0.02 - - - - - - - - 41.26

P/B

0.0 0.0 0.0 0.0 0.1 4.0 - - - - - - - - -

P/CF

0.3 0.3 0.2 0.1 0.3 - -6.9 -12.5 -14.9 -9.1 -18.2 56.9 93.8 56.1 -344.8

ROE %

16.98 19.85 19.51 12.37 9.96 12.58 - - - - - - - - -

ROA %

11.61 14.37 14.00 8.05 6.49 8.40 - - - - - - - - 14.53

ROCE %

19.81 23.24 24.21 14.83 13.33 20.55 - - - - - - - - 23.02

Current Ratio

3.2 3.6 3.5 2.9 2.9 1.8 - - 1.2 1.9 1.9 1.9 1.6 1.6 1.2

DSO

- - - - - 119.8 - - - - - - - - -

DIO

- - - - - 158.8 - - 166.8 149.6 148.5 155.5 - - 170.5

DPO

- - - - - 48.7 - - - - - - - - -

Operating Cycle

- - - - - 278.6 - - 166.8 149.6 148.5 155.5 - - 170.5

Cash Conversion Cycle

- - - - - 230.0 - - 166.8 149.6 148.5 155.5 - - 170.5

All numbers in INR currency

Quarterly Financial Ratios Dr. Reddy's Laboratories Limited

2025-Q4 2025-Q1 2024-Q4 2024-Q1 2023-Q4 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- 67.88 - 66.93 - 54.28 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- 86.2 - 81.4 - 68.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

56.34 16.98 - 19.85 - 19.51 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

39.98 11.61 - 14.37 - 14.00 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

67.26 19.81 - 23.24 - 24.21 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.6 3.2 3.5 3.6 2.9 3.5 - - - 2.9 - - - 2.9 - - - 3.0 - - - 2.6 - - - 2.3 - - - 2.3 - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in INR currency

Multiples are an important financial analysis tool for the company Dr. Reddy's Laboratories Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.64 5.92 % $ 691 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.99 4.33 % $ 255 M usaUSA
Alector Alector
ALEC
$ 2.19 2.1 % $ 226 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 5.08 0.96 % $ 50.2 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 45.83 0.22 % $ 7.55 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.79 0.28 % $ 395 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 248.37 0.14 % $ 32.5 B usaUSA
Altimmune Altimmune
ALT
$ 3.31 1.22 % $ 292 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.93 0.52 % $ 104 M usaUSA
Amgen Amgen
AMGN
$ 380.17 0.75 % $ 205 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 23.96 0.74 % $ 1.12 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.02 1.59 % $ 5.82 B irlandaIrlanda
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 17.23 1.29 % $ 5.4 B usaUSA
AbbVie AbbVie
ABBV
$ 261.94 1.87 % $ 463 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 54.77 1.67 % $ 1.58 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.22 1.7 % $ 304 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 70.92 1.04 % $ 1.42 B usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.76 2.03 % $ 4.97 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.87 2.75 % $ 590 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.04 1.38 % $ 3.3 B canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.89 2.41 % $ 523 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 15.23 3.39 % $ 417 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 3.54 0.14 % $ 853 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.3 1.84 % $ 192 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.35 1.95 % $ 3.1 B usaUSA
Artelo Biosciences Artelo Biosciences
ARTL
$ 5.15 1.1 % $ 974 K usaUSA
Arvinas Arvinas
ARVN
$ 8.44 0.41 % $ 598 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 80.24 0.11 % $ 10.7 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.86 0.64 % $ 324 M usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.25 6.87 % $ 39 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 9.49 1.17 % $ 119 M usaUSA
Agenus Agenus
AGEN
$ 7.12 2.59 % $ 212 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.3 1.26 % $ 2.19 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.94 2.93 % $ 516 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 5.34 0.47 % $ 435 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 491.2 2.47 % $ 38.4 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 216.73 0.75 % $ 10.8 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.0 0.5 % $ 12.6 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 72.33 0.1 % $ 13.9 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.2 0.92 % $ 1.72 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.87 0.13 % $ 268 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.03 2.52 % $ 115 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 24.35 1.5 % $ 2.41 B usaUSA
Biogen Biogen
BIIB
$ 217.62 0.22 % $ 31.9 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.48 0.2 % $ 6.11 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.22 0.82 % $ 12.7 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 64.03 0.61 % $ 130 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.11 0.08 % $ 498 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.35 1.13 % $ 953 M britainBritain